Placeholder Banner

BIO Files Amicus Brief on Case Addressing the America Invents Act’s Joinder Provision

December 28, 2018

BIO filed an amicus brief in Proppant Express Investments, LLC, Proppant Express Solutions, LLC, v. Oren Technologies, LLC in front of the Patent Trial and Appeal Board.

BIO members devote billions of dollars annually to researching and developing biotechnological healthcare, agricultural, environmental, and industrial products to cure diseases, improve food security, create alternative energy sources, and deliver many other benefits. However, these products typically require lengthy, costly, and resource-intensive research and development.

In light of these investments, BIO’s members depend upon a stable, predictable, and transparent patent system encouraging patent-holders to maintain and enforce strong patents. In particular, BIO’s members have a significant interest in ensuring the America Invents Act’s joinder provision, 35 U.S.C. § 315(c), is interpreted as Congress intended, and that only proper parties can join an existing inter partes review (IPR) proceeding.

Related Resources
IPR2018-00914 - Amicus Brief By BIO
Proppant Express Investments vs. Oren Technologies (BIO Brief as Amicus Curiae)
Discover More
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…